LT3297631T - Nk-1/nk-3 receptorių antagonistas, skirtas karščio pylimo gydymui - Google Patents

Nk-1/nk-3 receptorių antagonistas, skirtas karščio pylimo gydymui

Info

Publication number
LT3297631T
LT3297631T LT16723107T LT16723107T LT3297631T LT 3297631 T LT3297631 T LT 3297631T LT 16723107 T LT16723107 T LT 16723107T LT 16723107 T LT16723107 T LT 16723107T LT 3297631 T LT3297631 T LT 3297631T
Authority
LT
Lithuania
Prior art keywords
treatment
receptor antagonist
hot flushes
flushes
hot
Prior art date
Application number
LT16723107T
Other languages
English (en)
Inventor
Mike Trower
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of LT3297631T publication Critical patent/LT3297631T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Multicomponent Fibers (AREA)
LT16723107T 2015-05-18 2016-05-16 Nk-1/nk-3 receptorių antagonistas, skirtas karščio pylimo gydymui LT3297631T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562162870P 2015-05-18 2015-05-18
PCT/EP2016/060945 WO2016184829A1 (en) 2015-05-18 2016-05-16 Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases

Publications (1)

Publication Number Publication Date
LT3297631T true LT3297631T (lt) 2019-10-25

Family

ID=56008636

Family Applications (1)

Application Number Title Priority Date Filing Date
LT16723107T LT3297631T (lt) 2015-05-18 2016-05-16 Nk-1/nk-3 receptorių antagonistas, skirtas karščio pylimo gydymui

Country Status (21)

Country Link
US (3) US10195205B2 (lt)
EP (2) EP3574907B1 (lt)
JP (1) JP6902682B2 (lt)
KR (1) KR20180004815A (lt)
CN (4) CN107635557A (lt)
AU (2) AU2016264034B2 (lt)
BR (1) BR112017024852B1 (lt)
CA (1) CA2984591A1 (lt)
CY (1) CY1122180T1 (lt)
DK (1) DK3297631T3 (lt)
ES (1) ES2753539T3 (lt)
HR (1) HRP20192132T1 (lt)
HU (1) HUE047732T2 (lt)
LT (1) LT3297631T (lt)
MX (2) MX2017012720A (lt)
PL (1) PL3297631T3 (lt)
PT (1) PT3297631T (lt)
RS (1) RS59608B1 (lt)
RU (1) RU2743206C2 (lt)
SI (1) SI3297631T1 (lt)
WO (1) WO2016184829A1 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3384930A1 (en) 2013-03-15 2018-10-10 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding
AU2019233606A1 (en) * 2018-03-14 2020-09-17 KaNDy Therapeutics Limited Novel pharmaceutical formulation comprising dual NK-1/NK-3 receptor antagonists
CN112261942A (zh) * 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
CN114728906A (zh) 2019-11-15 2022-07-08 康堤医疗有限公司 制备nt-814的关键中间体6-氯-4-(4-氟-2-甲基苯基)吡啶-3-胺的新化学方法
KR20230043222A (ko) * 2020-08-12 2023-03-30 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
WO2023147135A1 (en) * 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Nk receptor antagonists for treatment of prostate cancer

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL186075B1 (pl) * 1994-05-27 2003-10-31 Smithkline Beechem Spa N-(-etylobenzylo)-3-hydroksy-2-fenylochinolino-4-karboksyamid oraz kompozycja farmaceutyczna zawierająca ten związek
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
CA2412355A1 (en) 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
EP1192952A3 (en) 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
WO2002089802A2 (en) * 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US7041682B2 (en) * 2002-07-03 2006-05-09 Schering Corporation NK1 antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
AU2003298369B2 (en) 2002-12-23 2009-08-27 Janssen Pharmaceutica N.V. Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists
US7525659B2 (en) 2003-01-15 2009-04-28 Negevtech Ltd. System for detection of water defects
BRPI0412291A (pt) 2003-07-03 2006-09-19 Hoffmann La Roche antagonistas duplos de nka/nk3 para o tratamento de esquizofrenia
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) * 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
WO2005110987A1 (en) 2004-05-12 2005-11-24 Pfizer Products Inc. Piperidine derivatives as nk1 and nk3 antagonists
DE102004033902A1 (de) 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
WO2006013205A1 (en) 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation
US20060030600A1 (en) 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders
BRPI0616459A2 (pt) * 2005-09-29 2011-06-21 Wyeth Corp compostos das fórmulas i, ii, e iii; processos para o tratamento ou para a prevenção de: um estado de saúde com melhora devido à recaptação de monoamina; pelo menos um sintoma vasomotor; pelo menos um distúrbio depressivo; pelo menos uma disfunção sexual; para a prevenção de dor; de distúrbio gastrointestinal ou genitourinário; de sìndrome de fadiga crÈnica; de sìndrome de fibromialgia; de esquizofrenia; e uso de um composto
WO2008116262A1 (en) * 2007-03-27 2008-10-02 Christopher Hovens Methods and compositions for treating prostate cancer
KR101163847B1 (ko) 2007-04-20 2012-07-09 에프. 호프만-라 로슈 아게 이중 ｎｋ1/ｎｋ3 수용체 길항제로서의 피롤리딘 유도체
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
MX2012002369A (es) * 2009-08-27 2012-03-29 Glaxosmithkline Llc Formas de anhidrato de un derivado de piridina.
US8415884B2 (en) 2009-09-08 2013-04-09 Tokyo Electron Limited Stable surface wave plasma source
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
MX2012013855A (es) * 2010-05-28 2013-04-08 Univ Texas Compuestos de oligobenzamida y su uso.
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
WO2014089019A1 (en) 2012-12-03 2014-06-12 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes

Also Published As

Publication number Publication date
EP3574907A1 (en) 2019-12-04
JP2018515445A (ja) 2018-06-14
RS59608B1 (sr) 2020-01-31
CY1122180T1 (el) 2020-11-25
RU2017134908A (ru) 2019-06-18
BR112017024852A2 (pt) 2018-08-07
KR20180004815A (ko) 2018-01-12
PL3297631T3 (pl) 2020-03-31
EP3297631B1 (en) 2019-09-04
DK3297631T3 (da) 2019-11-11
PT3297631T (pt) 2019-10-10
US20160339037A1 (en) 2016-11-24
HUE047732T2 (hu) 2020-05-28
US20210128574A1 (en) 2021-05-06
CA2984591A1 (en) 2016-11-24
AU2016264034A1 (en) 2017-10-26
WO2016184829A1 (en) 2016-11-24
RU2017134908A3 (lt) 2019-10-23
CN114306347A (zh) 2022-04-12
CN114272242A (zh) 2022-04-05
HRP20192132T1 (hr) 2020-02-21
CN107635557A (zh) 2018-01-26
RU2743206C2 (ru) 2021-02-16
AU2020201074A1 (en) 2020-03-05
EP3574907B1 (en) 2023-08-23
MX2020011668A (es) 2021-01-15
ES2753539T3 (es) 2020-04-13
JP6902682B2 (ja) 2021-07-14
US10195205B2 (en) 2019-02-05
US20210236506A1 (en) 2021-08-05
EP3574907C0 (en) 2023-08-23
SI3297631T1 (sl) 2019-12-31
CN114306335A (zh) 2022-04-12
MX2017012720A (es) 2018-02-09
AU2020201074B2 (en) 2021-07-29
BR112017024852B1 (pt) 2023-10-31
AU2016264034B2 (en) 2020-03-05
EP3297631A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
GB201514875D0 (en) Receptor
HK1252163A1 (zh) 受體
IL288321A (en) Methods for treating depression using orexin-2 receptor antagonists
PL3297631T3 (pl) Antagoniści receptora NK-1/NK-3 do leczenia uderzeń gorąca
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
HK1249095A1 (zh) Cgrp受體拮抗劑
IL258894A (en) Cgrp receptor antagonists
GB201702617D0 (en) Receptor
IL258893A (en) Cgrp receptor antagonists
IL284081A (en) Somatostatin receptor antagonistic compounds and methods of using them
IL263363A (en) Polymorph of nintedanib
EP3490606C0 (en) MINERALOCORTICOID RECEPTOR ANTAGONIST FOR THE TREATMENT OF OSTEOARTHRITIS
HUE054334T2 (hu) Angiotenzin-1-receptor antagonisták
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
PT3331517T (pt) Utilização da hidroxicarbamida para prevenir a não-perfusão da retina
HK1209575A2 (en) Isoquinolinone derivatives as nk3 antagonists nk3